Introduction
============

Fungal diseases are increasingly common major causes of human disease, especially in immunocompromised individuals and hospitalized patients with underlying medical conditions (Patterson, [@B24]; Caston-Osorio et al., [@B8]; Richardson and Lass-Florl, [@B30]; Pfaller and Diekema, [@B25]). In fact, since 1979 there has been a \>200% increase in the annual number of cases of invasive fungal infections (IFI) in the United States. IFIs rates have risen in large part due enhanced interventions in intensive care units (ICUs), increased survival rates of individuals with immunodeficiencies, and the increased administration of potent therapeutics, chemotherapeutics, and biologicals, that compromise the immune responses of our patients. This increase is best exemplified by the example of *Candida* spp.: *Candida* were once infrequent causes of invasive disease, whereas they are currently the fourth leading cause of nosocomial bloodstream infection in the United States, responsible for 8--15% of all such hospital acquired infections. However, despite the increased prevalence of many mycotic diseases, there remains an enormous gap in knowledge and our current therapeutic armamentarium all too often fails to eradicate these insidious pathogens.

Although they have powerful activities, the number of available medications for mycoses is significantly less than for bacterial diseases. At present, there are three main medication categories for IFI: azoles (fluconazole, itraconazole, voriconazole, and posaconazole), polyenes (primarily formulations of amphotericin B), and echinocandins (caspofungin, micafungin, and anidulafungin). Notably, both the azoles and polyenes target cell membrane sterols, with azoles inhibiting sterol synthesis and the polyenes purportedly disrupting the membrane structure. The echinocandins inhibit cell wall production by interfering with beta-1,3-glucan synthesis. In addition to these drugs, flucytosine, an antimetabolite, is utilized primarily in combination with amphotericin B for the treatment of cryptococcosis. Notably, the echinocandins are the last new class of antifungal drug, with caspofungin gaining FDA approval in by the FDA in 2001. Unfortunately, there is no antifungal medication poised to enter clinical medicine for the foreseeable future. Hence, there is a consensus that new approaches are needed to combat IFI.

Radioimmunotherapy (RIT) uses antigen--antibody interactions to deliver cytocidal amounts of ionizing radiation to specific cell targets. Currently, RIT is clinically utilized in the treatment of primary, refractory, and recurrent non-Hodgkin lymphoma using the radiolabeled mAbs Zevalin^®^ and Bexxar^®^. It is important to note that RIT offers several significant advantages over standard antifungal therapy. Firstly, RIT delivers lethal radiation, such that it does not merely interfere with a single cellular pathway but completely destroys targeted cells. As such, RIT is less subject to drug resistance mechanisms. Moreover, RIT is cidal in immunologically compromised individuals as the nuclides are equally able to destroy cell targets in immunologically intact individuals or those with HIV or other immunodeficiencies, either primary or drug induced. RIT does not suffer the drug--drug interactions that clinically trouble clinicians caring for complex patients, such as azole or echinocandin interactions with commonly prescribed immunosuppressive drugs, like cyclosporine or tacrolimus. Finally, in contrast to weeks, months, or years required for the treatment of certain mycoses with standard antifungals, RIT may permit single dose or a limited number of doses to combat fungal diseases.

What are the barriers for translating RIT into treatment approaches for infectious diseases? Cell surface antigens are well defined for diverse pathogens, including viruses, bacteria, parasites, and fungi. Moreover, monoclonal antibodies exist that target microbial cell surface antigens. Additionally, the technology for linking radionuclides to mAbs is well established, so the approaches can be readily translated from oncology into infectious diseases. Additionally, the US hospitals that are now regularly using RIT to treating cancer patients are fully equipped for initiating Infectious Diseases RIT. Included in this ability, imaging of patients receiving RIT to ascertain the targeting of radiolabeled mAbs in Infectious Diseases RIT can be readily achieved using portable imaging equipment that is standard in these hospitals. Hence, the time is "now" for developing RIT to combat IFI.

RIT of Infectious Diseases
==========================

Our laboratories were the first to demonstrate that microorganism-specific mAb-RIT is highly effective for the treatment of experimental fungal, bacterial, and viral infections, as well as virally induced cancers (Table [1](#T1){ref-type="table"}). Although the initial RIT work utilized *Cryptococcus neoformans* for proof-of-principle studies in 2003 (Dadachova et al., [@B12]), RIT of bacterial and viral pathogens also has rapidly progressed. In 2004, we established the feasibility of RIT for invasive bacterial infection using a mouse pneumococcal disease model (Dadachova et al., [@B10]). An IgM isotype mAb to serotype 8 *Streptococcus pneumoniae* capsular polysaccharide was conjugated to the alpha-particle emitter Bismuth-213 (^213^Bi) and we showed that an 80-μCi dose was sufficient to protect 60% of animals from an otherwise lethal challenge. More recently, in 2009, mAbs to the protective or lethal antigens of *Bacillus anthracis* labeled with either ^213^Bi or the beta-particle emitter rhenium-188 (^188^Re) were shown to prolong the survival of mice infected with *B. anthracis* Stern bacterial cells, but not spores (Rivera et al., [@B32]). Treatment with ^213^Bi was more effective than when less powerful beta-particles were used.

###### 

**List of monoclonal antibodies that have been used in experimental studies of radioimmunotherapy for infectious diseases**.

  Antibody            Isotype        Antigen recognized                       Reference or source
  ------------------- -------------- ---------------------------------------- ------------------------------------------------------------------------------
  D11                 IgM, human     Serotype 8 pneumococcal polysaccharide   Dadachova et al. ([@B10]), Zhong et al. ([@B40])
  7.5G                IgG2b, mouse   *B. anthracis* protective antigen        Rivera et al. ([@B31], [@B32])
  10F4                IgG1, mouse    *B. anthracis* protective antigen        Rivera et al. ([@B31], [@B32])
  14FA                IgG2b, mouse   *B. anthracis* lethal antigen            Rivera et al. ([@B32])
  18B7                IgG1, mouse    GXM, cryptococcal polysaccharide         Dadachova et al. ([@B12], [@B11], [@B14]), Bryan et al. ([@B6], [@B5])
  246-D (cluster I)   IgG1, human    HIV gp41                                 Dadachova et al. ([@B13])
  C1-P5               IgG1, mouse    HPV E6                                   Wang et al. ([@B39]), Phaeton et al. ([@B26],[@B27]), Harris et al. ([@B17])
  2G8                 IgG2b, mouse   Beta (1,3) glucan                        Torosantucci et al. ([@B38]), Rachini et al. ([@B28])
  4E12                IgG2a, mouse   Hsp60                                    Guimaraes et al. ([@B16])
  6D2                 IgM, mouse     Melanin                                  Rosas et al. ([@B33])
  B11                 IgM            Fungal glucosyl ceramide                 Rhome et al. ([@B29])

In 2006, HIV infected cells were found to be effectively targeted by RIT (Dadachova et al., [@B13]). Radiolabeling of antibody to the HIV-1 envelope glycoproteins gp120 and gp41 with ^213^Bi or ^188^Re selectively killed HIV infected cells *in vitro* and eliminated the majority of HIV infected cells injected into SCID mice. Notably, the mAb to gp41 is fully human. It is possible that, used in combination with anti-retroviral drugs, that RIT may provide a means to eradicate HIV infection (Casadevall et al., [@B7]). RIT has also proven to be highly effective in the treatment of virally induced cancers (Dadachova et al., [@B15]). Using a human papillomavirus (HPV) type 16-associated cervical cancer model in mice, RIT with a human mAb targeting the HPV16 E6 antigen significantly impeded tumor growth compared to cancers in control animals (Wang et al., [@B39]). Interestingly, RIT targeting cancer cells expressing low levels of HPV16 E6 was also successful (Phaeton et al., [@B26]). Furthermore, pre-treatment of the cervical tumors with a proteosome inhibitor, MG-132, and unlabeled antibody to E6 resulted in an increase in the levels of E6 for targeting by ^188^Re-labeled mAb and enhanced the efficacy of RIT (Phaeton et al., [@B27]). These studies also suggest that RIT could potentially eradicate infected cells prior to their malignant transformation. In addition to cervical cancer, RIT proof-of-principle experiments with HPV-associated head and neck squamous cell carcinoma suggest that this modality may be effective for this difficult to combat disease (Harris et al., [@B17]).

RIT of Cryptococcosis
=====================

*Cryptococcus neoformans* is a yeast-like encapsulated fungus with a global distribution that is responsible for ∼600,000 deaths annually (Park et al., [@B23]), particularly in individuals with HIV infection. As noted above, the first RIT experiments published in 2003 utilized *C. neoformans* as a model organism (Dadachova et al., [@B12]). The initial studies with *C. neoformans* demonstrated that a mAb specific for glucuronoxylomannan (GXM), the major component of the pathogen's polysaccharide capsule, radiolabeled with either ^213^Bi or ^188^Re efficiently killed cryptococcal cells *in vitro* and significantly reduced fungal burdens in and prolonged the survival of lethally infected mice (Dadachova et al., [@B12]). Most impressively, 60% of infected mice treated with 100 μCi ^213^Bi were alive at day 75 after RIT. Importantly, systemically infected mice tolerated activities of up to 150 μCi of mAb labeled with either nuclide with platelet counts normalizing by 14 days post-treatment (Dadachova et al., [@B11]). The reduction in platelets in the infected mice was similar to that seen in the setting of cancer therapy (Sharkey et al., [@B34]; Behr et al., [@B1]). Additionally, these mice had no evidence of pulmonary fibrosis 5 months after receiving RIT. The lack of severe toxicities due to radiation in the mice with cryptococcosis treated with RIT is presumably due to the high specificity of the mAb.

Chemotherapy for severe cryptococcosis is based on the administration of amphotericin B. However, RIT was recently shown to be more effective than amphotericin B for the treatment of disseminated cryptococcosis (Bryan et al., [@B5]). In the murine model examined, amphotericin B was able to prolong survival, but fungal burdens were not significantly reduced. In contrast, RIT significantly reduced the fungal burdens in the tissues examined, regardless of the melanization state of the yeast cell. This is an important observation as *C. neoformans* can produce melanin along the yeast cell wall and this pigment can protect the fungus from injury from external radiation (Nosanchuk and Casadevall, [@B22]; Dadachova et al., [@B9]). Interestingly, ∼10 times less mAb 18B7 conjugated to ^213^Bi was required for killing melanized *C. neoformans* yeast cells than ^188^Re conjugated antibody (Bryan et al., [@B5]), demonstrating the superior penetrating power of the alpha-particle versus the beta-particle emitter. Combining RIT with amphotericin B was more effective than amphotericin B alone (Bryan et al., [@B5]). However, combination therapy was less potent than RIT alone if melanized fungal cells were used for the infectious challenge. It is not clear whether this result is due to the potential toxicities of the amphotericin or the inflammatory responses that are induced upon infection with melanized yeast cells (Mednick et al., [@B21]).

Although drug resistance is a concern in the treatment of fungal infections, there is no literature on pathogen resistance to RIT. Nevertheless, experiments have been performed to assess whether resistance can develop (Bryan et al., [@B6]). *C. neoformans* yeast cells were harvested from infected mice that received RIT and subjected to treatment with ^213^Bi or ^188^Re conjugated mAbs. Notably, the RIT and radiation naive *C. neoformans* yeast cells were similarly radiosensitive to the radiolabeled mAbs. Additionally, no differences in survival occurred comparing mice infected with RIT *C. neoformans* to radiation naive yeast cells.

Mechanism
=========

Although the precise mechanism of action is not known, there are major radiobiological probabilities for the effectiveness of RIT. The first and most targeted effect occurs by a "direct hit," when the radiolabeled antibody binds to a cell and the emitted particles kill the cell (Figure [1](#F1){ref-type="fig"}A). However, "cross-fire" effects, killing of a cell by particles emitted from a radiolabeled antibody bound to a distant cell, can be equally efficient (Figure [1](#F1){ref-type="fig"}B). Both of these mechanisms lead to cell apoptosis and cell cycle redistribution (Macklis, [@B18]). It is also highly probable, that a radiolabeled antibody could kill by both of these processes. Notably, the "cross-fire" mechanism would be expected to play a large role in combating fungal biofilm diseases or situations where some fungi are extracellular, whilst others are intracellular.

![**Proposed mechanism of RIT**. **(A)** "Direct hit," where emitted particles kills the cell bound by radiolabeled antibody. **(B)** "Cross-fire," where emitted particles kill cells distant from the cell bound by radiolabeled antibody. Image is epithelial tissue infected with *Candida parapsilosis*.](fmicb-02-00283-g001){#F1}

Certain mechanisms of radiation effects on fungi have been studied using *C. neoformans*. *C. neoformans* yeast cells can be directly killed by gamma, beta, and alpha radiation in a dose and time dependent manner (Bryan et al., [@B4]). Notably, although membrane permeability did occur, it does not appear to be the primary cause of death. Gamma radiation induced significantly more membrane disruption than either beta or alpha radiation. All forms of radiation induced cellular apoptosis, although external gamma radiation and ^188^Re-labeled antibody induced more apoptosis than ^213^Bi-labeled antibody. However, ^213^Bi-labeled antibody significantly reduced the metabolic activity of the yeast cells, whereas the other forms of radiation did not. Hence, the cellular effects of radiation on yeast are dependent on dose and time as well as the form of radiation administered. In a more recent study, gamma radiation, as well as UV and visible light, were shown to affect ATP levels in *C. neoformans* yeast cells, and this effect was more pronounced in melanized compared to non-melanized cells (Bryan et al., [@B2]). Another study assessed whether "direct hit" or "cross-fire" predominated in the killing of *C. neoformans* yeast cells (Dadachova et al., [@B14]). As expected, given the power of alpha radiation, ^213^Bi-labeled antibody resulted in significant "direct hit" killing. However, ^213^Bi-labeled antibody bound to heat-killed yeast cells also led to "cross-fire" fungicidal effects. In contrast, the killing with the lower energy beta-particles produced by the ^188^Re-labeled antibody was primarily due to "cross-fire."

RIT Toxicities
==============

As briefly described above, the primary toxicity identified in our RIT experiments is a modest thrombocytopenia that resolves within 14 days post therapy, which is similar to that seen in RIT in cancer patients (Macklis and Pohlman, [@B19]). Importantly, thrombocytopenia prediction models are developed for RIT and dose-fractionated RIT strategies can be implemented to minimize the nadir and duration of the thrombocytopenia (Shen et al., [@B35]). Importantly, since microbial cells in otherwise sterile sites are foreign to hosts, the microbes display antigens that are distinct from those expressed by host cells. These distinct microbial antigens are the primary targets for infectious diseases RIT. In contrast, RIT of cancers targets tumor-associated antigens that are also expressed on normal cells, which clearly increases toxicity risks. Therefore, in addition to leading to a theoretically higher therapeutic index in infectious diseases RIT relative to that for cancer, RIT of infectious diseases should have a lower toxicity risk than RIT for cancer.

There is an important issue of "free antigen" as pathogens release/secrete many substances, including proteins, carbohydrates, and lipids. Hence, antibody directed to released or potentially secreted antigen has the potential to produce off-target effects. Previously, we have studied this issue in murine cryptococcosis, since *C. neoformans* releases large amounts of capsular polysaccharide and we were concerned that the radiolabeled antibody to the capsule would interact with non-organism associated polysaccharide. However, we determined that radiolabeled antibody had higher affinity for mice-associated polysaccharide than for its soluble form (Dadachova et al., [@B12]). Nevertheless, unlabeled antibody can be administered prior to RIT in order to potentially clear circulating antigens.

Biofilms
========

Biofilms are complex communities of pathogens that adhere to one another and are typically surrounded by a matrix of extracellular materials, particularly exopolysaccharides. Fungal biofilms can be especially tenacious and can exacerbate disease by leading to increased drug resistance or enhanced adherence to foreign bodies or tissues. RIT using mAb to *C. neoformans* GXM conjugated to ^213^Bi can effectively damage cryptococcal biofilms (50% reduction in metabolic activity; Martinez et al., [@B20]). Notably, beta and gamma forms of radiation did not have a significant effect on the fungal biofilms. It was not determined whether RIT of biofilms synergized with antifungal drugs, as the alterations in biofilm could enhance drug penetration facilitating the activities of the drugs on fungal cells. Hence, RIT may be a means for combating fungal biofilms with or without concomitant antifungal drugs.

Concept of PAN-FUNGAL RIT
=========================

To dramatically drive the treatment of infectious diseases forward with RIT, we need to make a "quantum leap" by identifying antigens shared by major IFI-causing pathogens (PAN-FUNGAL antigens) in order to deliver RIT without the need for specific mycological diagnosis or fear of drug resistance. To this end, we have been exploring the possibility of targeting common cell wall associated antigens, which also happen to constitute major virulence factors for these fungi. We have begun exploring the utility of four cell surface antigens. The majority of fungal cells, yeast, and hyphal, display beta-glucans on their cell surface and Cassone and colleagues have generated a mAb to beta-glucan that provides significant protection against *Candida albicans, C. neoformans*, and *Aspergillus fumigatus* in animal models if given prior to infection (Torosantucci et al., [@B37], [@B38]; Rachini et al., [@B28]). Heat shock protein 60 (Hsp60) is a key regulator of virulence in *Histoplasma capsulatum* and mAbs directed to this protein are protective in murine histoplasmosis (Guimaraes et al., [@B16]). Recently, we demonstrated that mAbs to *H. capsulatum* Hsp60 also bound other pathogenic fungal species (Bryan et al., [@B3]), but does not react with human Hsp60 (Guimaraes et al., [@B16]). Melanin is present in the cell wall of diverse human fungal pathogens and a monoclonal to fungal melanin has been shown to bind *C. neoformans, H. capsulatum, Aspergillus* spp., *C. albicans, Scytalidium dimidiatum, Sporothrix schenckii, Paracoccidioides brasiliensis*, *Coccidioides posadasii*, and *Blastomyces dermatitidis* (reviewed in Nosanchuk and Casadevall, [@B22]; Taborda et al., [@B36]). Glucosylceramide is another common exposed cell surface antigen on fungi and a mAb to glucosylceramide has been shown to bind glucosylceramide in *C. neoformans* and *C. albicans*, but not mammalian glucosylceramide (Rhome et al., [@B29]).

Selected mAbs to these four surface antigens were used for radiolabeling and tested for their capacity to kill *C. neoformans* and *C. albicans* (Bryan et al., [@B3]). ^213^Bi-labeled \>90% of mAbs 2G8, IgG2b to beta-galactan, and 4E12, IgG2a to Hsp60, but the labeling efficiency of mAb 6D2, IgM to melanin, was only 30%. ^213^Bi did not effectively label mAb B11, IgM to glucosylceramide, but the mAb was labeled by ^188^Re. Radiolabeled mAb to beta-glucan killed 100% of *C. neoformans* yeast cells, whereas *C. albicans* pseudohyphal cells were significantly more resistant as the treatment produced a 30% reduction in CFUs. Targeting Hsp60 produced \> 90% reductions in CFUs of both *C. neoformans* and *C. albicans*. The poor ^213^Bi radiolabeling of the mAb to melanin resulted in the delivery of three to four times less radiation than the ^213^Bi-labeled mAbs to beta-glucan and Hsp60, and ∼4 μCi/5 million yeast cells was the maximal radiation delivered resulting in only 15 and 22% reduction for *C. albicans* and *C. neoformans*, respectively, but the decrease was only significant for *C. neoformans*. The ^188^Re-labeled mAb to glucosylceramide decreased the CFU of *C. neoformans* by 40%. Hence, we have demonstrated that we can radiolabel diverse antibodies to distinct conserved surface antigens and deliver cytocidal radiation to important fungal pathogens by RIT. It is noteworthy that the efficacy of killing was achieved with significantly lower (∼1,000 times) concentrations than were required for biological efficacy with unlabeled antibody, such as with mAb 2G8 (Torosantucci et al., [@B38]). Moreover, the data demonstrated that the powerful alpha particles from ^213^Bi efficiently killed fungal cells even when there were relatively few binding sites on their cell surface (∼5% mAb binding). Additional experimentation is required to develop more efficient labeling of IgM isotype mAbs and perhaps improve the labeling of IgG isotype mAbs. Nevertheless, the PAN-FUNGAL concept is validated by these proof-of-principle experiments and further study is clearly warranted.

Discussion
==========

The drive to develop RIT of infectious diseases is fueled by the facts that (1) our current antifungal armamentarium often fails to eradicate IFI, (2) the last new category of antifungals was FDA approved in 2001, (3) no new antifungal drugs are close to clinical availability, and (4) RIT is a means to specifically target microbes in a cytocidal manner, irrespective of the host immune status, current drug regimen, or potential resistance mechanisms of the microbe. With RIT of fungi, especially with PAN-FUNGAL RIT, we can potentially reduce treatment durations, prevent the toxicities of the prolonged administration of (possibly ineffective) antifungals, minimize concerns of drug--drug interactions, permit the preservation of current immunomodulating medications (i.e., for transplant patients), and eliminate the need for a specific mycological diagnosis. Given the well developed applications of RIT in Oncology, the barriers to initiating RIT for infectious diseases, especially IFIs that continue to have unacceptably high mortality rates, are indeed surmountable. The work to date demonstrates that we have in hand a diverse set of specific mAbs and mAbs with reactivity to several leading fungal pathogens that can be harnessed for RIT. We are hopeful that the upcoming years will see a broader acceptance of this approach and a rapid growth in pre-clinical work that will allow the translation of RIT from the basic science laboratory to our patients.
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